BlossomHill Therapeutics (BLSM)
Develops oral small-molecule cancer therapies for EGFR, CLK and KRAS targets.
Something off on this page? Send us feedback.
Develops oral small-molecule cancer candidates targeting EGFR resistance, CLK-mediated RNA splicing and KRAS. With no approved products, the wholly owned pipeline is a clinical-stage research-and-development business that relies on trial execution, regulatory progress and further financing.
Develops wholly owned oral small-molecule programs for EGFR-mutant non-small cell lung cancer, acute myeloid leukemia and higher-risk myelodysplastic syndromes, and KRAS-driven tumors. Its brain-active OMNI-EGFR inhibitor is in the SOLARA study; its CLK inhibitor is in a dose-escalation study; and its pan-KRAS inhibitor remains preclinical.
Uses intentional chemistry to select targets with unresolved gaps and create new scaffolds around protein dynamics, seeking potency, mutation coverage, selectivity, durability, oral exposure and manufacturability. Operates without product revenue or approved products and depends on clinical, regulatory and financing progress to commercialize. Trial execution relies on research organizations, clinical sites, laboratories and contract manufacturers; the pipeline and intellectual-property estate are wholly owned.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | Leerink Partners | Reiterate | Rating: —Target: $36 | Target: $40 |
| Sep 21, 2026 | Guggenheim | Reiterate | Rating: —Target: $30 | Target: $40 |
| Sep 1, 2026 | Leerink Partners | Target | Target: — | Target: $36 |
| Sep 1, 2026 | Guggenheim | Initiate | Rating: —Target: — | Target: $30 |
| Sep 1, 2026 | H.C. Wainwright | Initiate | Rating: —Target: — | Target: $35 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $95.4M · Total debt $23.4M · Total assets $124.1M · Shareholders' equity $82.0M
- Revenue
- $0
- Operating income
- −$24.7M
- Net income
- −$23.8M
No dividends on record.
No ownership filings on record for this listing.
- Johnson & Johnson
Approved EGFR regimens contest front-line and resistant NSCLC.
- AstraZeneca (ADR)
TAGRISSO sets the EGFR-mutant NSCLC standard of care.
- Black Diamond Therapeutics
Oral fourth-generation EGFR TKI targets C797S resistance.
- Revolution Medicines
Late-stage RAS(ON) portfolio challenges pan-KRAS development.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BlossomHill Therapeutics | $23.02 | −8.83% | $734.3M | — | — | — | — |
| Johnson & Johnson | $268.43 | −0.28% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| AstraZeneca (ADR) | $164.41 | −2.35% | $261.12B | 25.3 | 15.5 | 4.3 | +6.4% |
| Black Diamond Therapeutics | $1.88 | −5.30% | $113.5M | — | — | — | — |
| Revolution Medicines | $190.98 | −0.98% | $41.00B | — | — | — | — |
| Median | 28.2 | 19.0 | 5.4 | +6.5% |